Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.

Date publication

mars 2018

Journal

Alimentary pharmacology & therapeutics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Serrero M, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-Biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29315694

Résumé

Long-term outcome of ustekinumab in Crohn's disease (CD) has not been evaluated.

Mots clés

Adult, Cohort Studies, Crohn Disease, drug therapy, Drug Resistance, drug effects, Endoscopy, Female, Follow-Up Studies, Humans, Male, Pregnancy, Retrospective Studies, Time Factors, Treatment Outcome, Tumor Necrosis Factor-alpha, therapeutic use, Ustekinumab, administration & dosage

Référence

Aliment. Pharmacol. Ther.. 2018 Mar;47(5):588-595